{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:58:05Z","timestamp":1790139485294,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s11864-025-01319-3","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T09:21:11Z","timestamp":1744795271000},"page":"367-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emerging Advances in the Molecular Landscape of Penile Cancer and Their Implications for Precision Medicine"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7516-8762","authenticated-orcid":false,"given":"Laura","family":"Elst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5212-5020","authenticated-orcid":false,"given":"Kaat","family":"Vandermaesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-6586","authenticated-orcid":false,"given":"Maarten","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"issue":"1","key":"1319_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-021-00246-5","volume":"7","author":"A Thomas","year":"2021","unstructured":"Thomas A, Necchi A, Muneer A, Tobias-Machado M, Tran ATH, Van Rompuy A-S, et al. Penile cancer. Nat Rev Dis Primers. 2021;7(1):11.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"1319_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(18)30682-X","volume":"20","author":"TB Olesen","year":"2019","unstructured":"Olesen TB, Sand FL, Rasmussen CL, Albieri V, Toft BG, Norrild B, et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2019;20(1):145\u201358.","journal-title":"Lancet Oncol"},{"issue":"24","key":"1319_CR3","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.3390\/cancers14246024","volume":"14","author":"J Chahoud","year":"2022","unstructured":"Chahoud J, Zacharias NM, Pham R, Qiao W, Guo M, Lu X, et al. Prognostic significance of p16 and its relationship with human papillomavirus status in patients with penile squamous cell carcinoma: results of 5 Years Follow-Up. Cancers (Basel). 2022;14(24):6024.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"1319_CR4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.juro.2014.08.087","volume":"193","author":"RS Djajadiningrat","year":"2015","unstructured":"Djajadiningrat RS, Jordanova ES, Kroon BK, van Werkhoven E, de Jong J, Pronk DT, et al. Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome. J Urol. 2015;193(2):526\u201331.","journal-title":"J Urol"},{"key":"1319_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2025.101185","volume":"55","author":"U Dhasthakeer","year":"2025","unstructured":"Dhasthakeer U, Jha AN, Gupta AK. Comparison of efficacy and toxicity of chemotherapeutic regimens used as adjuvant and\/or neoadjuvant chemotherapy in penile cancer patients. Curr Probl Cancer. 2025;55: 101185.","journal-title":"Curr Probl Cancer"},{"issue":"5","key":"1319_CR6","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.euo.2020.10.011","volume":"4","author":"M Bandini","year":"2021","unstructured":"Bandini M, Ross JS, Zhu Y, Ye DW, Ornellas AA, Watkin N, et al. Association between human papillomavirus infection and outcome of perioperative nodal radiotherapy for penile carcinoma. Eur Urol Oncol. 2021;4(5):802\u201310.","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"1319_CR7","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00345-018-2280-0","volume":"36","author":"Z Yuan","year":"2018","unstructured":"Yuan Z, Naghavi AO, Tang D, Kim Y, Ahmed KA, Dhillon J, et al. The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. World J Urol. 2018;36(9):1431\u201340.","journal-title":"World J Urol"},{"issue":"31","key":"1319_CR8","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1200\/JCO.22.02894","volume":"41","author":"HM de Vries","year":"2023","unstructured":"de Vries HM, Rafael TS, Gil-Jimenez A, de Feijter JM, Bekers E, van der Laan E, et al. Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis (The PERICLES Study): A phase II trial. J Clin Oncol. 2023;41(31):4872\u201380.","journal-title":"J Clin Oncol"},{"key":"1319_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2024.03.038","volume":"86","author":"L Elst","year":"2024","unstructured":"Elst L, Philips G, Vandermaesen K, Bassez A, Lodi F, Vreeburg MTA, et al. Single-cell atlas of penile cancer reveals TP53 mutations as a driver of an aggressive phenotype, irrespective of human papillomavirus status, and provides clues for treatment personalization. Eur Urol. 2024;86:114.","journal-title":"Eur Urol"},{"issue":"19","key":"1319_CR10","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.3390\/cancers15194748","volume":"15","author":"JN Mink","year":"2023","unstructured":"Mink JN, Khalmurzaev O, Pryalukhin A, Geppert CI, Lohse S, Bende K, et al. Evaluation of prognostic parameters to identify aggressive penile carcinomas. Cancers (Basel). 2023;15(19):4748.","journal-title":"Cancers (Basel)"},{"key":"1319_CR11","doi-asserted-by":"crossref","unstructured":"Brouwer OR, Albersen M, Parnham A, et al. European association of urology\u2013American society of clinical oncology collaborative guideline on penile cancer: 2023 update. Eur Urol. 2023;83:548\u201360.","DOI":"10.1016\/j.eururo.2023.02.027"},{"issue":"3","key":"1319_CR12","first-page":"352","volume":"23","author":"A Chaubey","year":"2024","unstructured":"Chaubey A, Tiwari S, Suryavanshi P, Jain V. Quality of life evaluation after partial penile amputation for penile cancer. Ann Afr Med. 2024;23(3):352\u20137.","journal-title":"Ann Afr Med"},{"issue":"4","key":"1319_CR13","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.juro.2014.04.014","volume":"192","author":"JM Kieffer","year":"2014","unstructured":"Kieffer JM, Djajadiningrat RS, van Muilekom EA, Graafland NM, Horenblas S, Aaronson NK. Quality of life for patients treated for penile cancer. J Urol. 2014;192(4):1105\u201310.","journal-title":"J Urol"},{"issue":"6","key":"1319_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/JU.0000000000000746","volume":"203","author":"M Azizi","year":"2020","unstructured":"Azizi M, Aydin AM, Hajiran A, Lai A, Kumar A, Peyton CC, et al. Systematic review and meta-analysis-is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma? J Urol. 2020;203(6):1147\u201355.","journal-title":"J Urol"},{"issue":"6","key":"1319_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.urolonc.2020.08.001","volume":"40","author":"J Chahoud","year":"2022","unstructured":"Chahoud J, Tamil M, Necchi A. Second line salvage systemic therapy for advanced penile cancer. Urol Oncol. 2022;40(6):229\u201334.","journal-title":"Urol Oncol"},{"issue":"11","key":"1319_CR16","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.3390\/jpm13111623","volume":"13","author":"K Rouvinov","year":"2023","unstructured":"Rouvinov K, Mazor G, Kozlener E, Meirovitz A, Shrem NS, Abu Saleh O, et al. Cemiplimab as first line therapy in advanced penile squamous cell carcinoma: a real-world experience. J Pers Med. 2023;13(11):1623.","journal-title":"J Pers Med."},{"issue":"24","key":"1319_CR17","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-15-1004","volume":"75","author":"AS McDaniel","year":"2015","unstructured":"McDaniel AS, Hovelson DH, Cani AK, Liu C-J, Zhai Y, Zhang Y, et al. Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy. Can Res. 2015;75(24):5219\u201327.","journal-title":"Can Res"},{"issue":"3","key":"1319_CR18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.juro.2018.09.056","volume":"201","author":"JM Jacob","year":"2019","unstructured":"Jacob JM, Ferry EK, Gay LM, Elvin JA, Vergilio JA, Ramkissoon S, et al. Comparative genomic profiling of refractory and metastatic penile and nonpenile cutaneous squamous cell carcinoma: implications for selection of systemic therapy. J Urol. 2019;201(3):541\u20138.","journal-title":"J Urol"},{"issue":"24","key":"1319_CR19","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1002\/cncr.34982","volume":"129","author":"B Nazha","year":"2023","unstructured":"Nazha B, Zhuang T, Wu S, Brown JT, Magee D, Carthon BC, et al. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers. Cancer. 2023;129(24):3884\u201393.","journal-title":"Cancer"},{"key":"1319_CR20","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.euf.2022.04.012","volume":"8","author":"L Elst","year":"2022","unstructured":"Elst L, Van Rompuy AS, Roussel E, Spans L, VandenBempt I, Necchi A, et al. Establishment and characterization of advanced penile cancer patient-derived tumor xenografts: paving the way for personalized treatments. Eur Urol Focus. 2022;8:1787.","journal-title":"Eur Urol Focus"},{"issue":"5","key":"1319_CR21","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.pathol.2023.03.010","volume":"55","author":"J Hrudka","year":"2023","unstructured":"Hrudka J, Prouzova Z, Kendall Bartu M, Hojny J, Capka D, Zavillova N, et al. Immune cell infiltration, tumour budding, and the p53 expression pattern are important predictors in penile squamous cell carcinoma: a retrospective study of 152 cases. Pathology. 2023;55(5):637\u201349.","journal-title":"Pathology"},{"key":"1319_CR22","doi-asserted-by":"crossref","unstructured":"Trias I, Algaba F, de Torres I, Saco A, Marimon L, Pe\u00f1uelas N, et al. p53 Immunohistochemistry defines a subset of human papillomavirus-independent penile squamous cell carcinomas with adverse prognosis. Am J Surg Pathol. 2025;49(2):190\u2013193.","DOI":"10.1097\/PAS.0000000000002341"},{"issue":"12","key":"1319_CR23","doi-asserted-by":"publisher","first-page":"e2348002","DOI":"10.1001\/jamanetworkopen.2023.48002","volume":"6","author":"A Necchi","year":"2023","unstructured":"Necchi A, Spiess PE, Costa de Padua T, Li R, Grivas P, Huang RSP, et al. Genomic profiles and clinical outcomes of penile squamous cell carcinoma with elevated tumor mutational burden. JAMA Netw Open. 2023;6(12):e2348002.","journal-title":"JAMA Netw Open"},{"key":"1319_CR24","doi-asserted-by":"crossref","unstructured":"Gandara DR, et al. Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types. JCO. 2023;41:2503-2503.","DOI":"10.1200\/JCO.2023.41.16_suppl.2503"},{"issue":"3 Pt 1","key":"1319_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","volume":"197","author":"SR Ottenhof","year":"2017","unstructured":"Ottenhof SR, Djajadiningrat RS, de Jong J, Thygesen HH, Horenblas S, Jordanova ES. Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status. J Urol. 2017;197(3 Pt 1):690\u20137.","journal-title":"J Urol"},{"key":"1319_CR26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3389\/fimmu.2018.01253","volume":"9","author":"SR Ottenhof","year":"2018","unstructured":"Ottenhof SR, Djajadiningrat RS, Thygesen HH, Jakobs PJ, Jozwiak K, Heeren AM, et al. The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma. Front Immunol. 2018;9:1253.","journal-title":"Front Immunol"},{"issue":"7","key":"1319_CR27","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/cancers12071796","volume":"12","author":"C Chu","year":"2020","unstructured":"Chu C, Yao K, Lu J, Zhang Y, Chen K, Lu J, et al. Immunophenotypes based on the tumor immune microenvironment allow for unsupervised penile cancer patient stratification. Cancers (Basel). 2020;12(7):1796.","journal-title":"Cancers (Basel)."},{"issue":"4","key":"1319_CR28","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jamaoncol.2015.6326","volume":"2","author":"BE Howitt","year":"2016","unstructured":"Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, et al. Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA Oncol. 2016;2(4):518\u201322.","journal-title":"JAMA Oncol"},{"key":"1319_CR29","doi-asserted-by":"publisher","unstructured":"Maluf FC, et al. A phase II trial of pembrolizumab combined with platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.\u00a0JCO. 2023;41:TPS14\u2013TPS14. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.TPS14.","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS14"},{"key":"1319_CR30","doi-asserted-by":"publisher","unstructured":"Bahl A, et al. EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma. JCO. 2025;43:1\u20131. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.1.","DOI":"10.1200\/JCO.2025.43.5_suppl.1"},{"key":"1319_CR31","doi-asserted-by":"publisher","unstructured":"Challapalli A, et al. EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma. JCO. 2025;43:9\u20139. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.9.","DOI":"10.1200\/JCO.2025.43.5_suppl.9"},{"issue":"2","key":"1319_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00262-023-03615-z","volume":"73","author":"J Zhang","year":"2024","unstructured":"Zhang J, Wang Y, Huang Y, Tan X, Xu J, Yan Q, et al. Characterization of T cell receptor repertoire in penile cancer. Cancer Immunol Immunother. 2024;73(2):24.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"1319_CR33","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41591-021-01323-8","volume":"27","author":"A Bassez","year":"2021","unstructured":"Bassez A, Vos H, Van Dyck L, Floris G, Arijs I, Desmedt C, et al. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nat Med. 2021;27(5):820\u201332.","journal-title":"Nat Med"},{"issue":"1","key":"1319_CR34","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.1038\/s41467-023-43381-1","volume":"14","author":"S Cappuyns","year":"2023","unstructured":"Cappuyns S, Philips G, Vandecaveye V, Boeckx B, Schepers R, Van Brussel T, et al. PD-1(-) CD45RA(+) effector-memory CD8 T cells and CXCL10(+) macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma. Nat Commun. 2023;14(1):7825.","journal-title":"Nat Commun"},{"key":"1319_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682030","volume":"12","author":"TS Rafael","year":"2021","unstructured":"Rafael TS, de Vries HM, Ottenhof SR, Hofland I, Broeks A, de Jong J, et al. Distinct patterns of myeloid cell infiltration in patients with hrHPV-positive and hrhpv-negative penile squamous cell carcinoma: the importance of assessing myeloid cell densities within the spatial context of the tumor. Front Immunol. 2021;12: 682030.","journal-title":"Front Immunol"},{"issue":"1","key":"1319_CR36","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41467-020-15980-9","volume":"11","author":"T Huang","year":"2020","unstructured":"Huang T, Cheng X, Chahoud J, Sarhan A, Tamboli P, Rao P, et al. Effective combinatorial immunotherapy for penile squamous cell carcinoma. Nat Commun. 2020;11(1):2124.","journal-title":"Nat Commun"},{"issue":"8","key":"1319_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485\u201398.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1319_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/cancers16020303","volume":"16","author":"F Ionescu","year":"2024","unstructured":"Ionescu F, Nguyen J, Segura CM, Paravathaneni M, Grass GD, Johnstone P, et al. Multiplex immunofluorescence captures progressive immune exhaustion with advancing penile squamous cell cancer stage. Cancers (Basel). 2024;16(2):303.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1319_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12967-023-04281-6","volume":"21","author":"Z Peng","year":"2023","unstructured":"Peng Z, Ren Z, Tong Z, Zhu Y, Zhu Y, Hu K. Interactions between MFAP5 + fibroblasts and tumor-infiltrating myeloid cells shape the malignant microenvironment of colorectal cancer. J Transl Med. 2023;21(1):405.","journal-title":"J Transl Med"},{"key":"1319_CR40","doi-asserted-by":"publisher","unstructured":"Stenzel PJ, Thomas A, Schindeldecker M, Macher-Goeppinger S, Porubsky S, Haferkamp A, Tsaur I, Roth W, Tagscherer KE. Tumor-infiltrating plasma cells are a prognostic factor in penile squamous cell carcinoma. Virchows Arch. 2025. https:\/\/doi.org\/10.1007\/s00428-024-04013-1.","DOI":"10.1007\/s00428-024-04013-1"},{"issue":"1","key":"1319_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12885-025-13484-7","volume":"25","author":"X Liu","year":"2025","unstructured":"Liu X, Lv W, Huang D, Cui H. The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of lung cancer patients: a systematic review and meta-analysis. BMC Cancer. 2025;25(1):87.","journal-title":"BMC Cancer"},{"key":"1319_CR42","doi-asserted-by":"publisher","first-page":"1414884","DOI":"10.3389\/fimmu.2024.1414884","volume":"15","author":"B Jiang","year":"2024","unstructured":"Jiang B, Wu Z, Zhang Y, Yang X. Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis. Front Immunol. 2024;15:1414884.","journal-title":"Front Immunol"},{"key":"1319_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2022.12.008","volume":"49","author":"GD Grass","year":"2023","unstructured":"Grass GD, Chahoud J, Lopez A, Dhillon J, Eschrich SA, Johnstone PAS, et al. An Analysis of Nectin-4 (PVRL4) in Penile Squamous Cell Carcinoma. Eur Urol Open Sci. 2023;49:1\u20135.","journal-title":"Eur Urol Open Sci"},{"key":"1319_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","volume":"142","author":"B Tekin","year":"2023","unstructured":"Tekin B, Cheville JC, Herrera Hernandez L, Negron V, Smith CY, Jenkins SM, et al. Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. Hum Pathol. 2023;142:42\u201350.","journal-title":"Hum Pathol"},{"issue":"22","key":"1319_CR45","doi-asserted-by":"publisher","first-page":"16109","DOI":"10.3390\/ijms242216109","volume":"24","author":"CC Fahey","year":"2023","unstructured":"Fahey CC, Nebhan CA, York S, Davis NB, Hurley PJ, Gordetsky JB, et al. Metastatic penile squamous cell carcinoma responsive to enfortumab vedotin. Int J Mol Sci. 2023;24(22):16109.","journal-title":"Int J Mol Sci."},{"issue":"4","key":"1319_CR46","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bju.16442","volume":"134","author":"R Weiten","year":"2024","unstructured":"Weiten R, Storz E, Kessler C, Sperber L, Spohn HE, Pfister D, et al. Trophoblast cell surface antigen-2: a promising new biomarker and potential therapeutic target in penile squamous cell carcinoma. BJU Int. 2024;134(4):615\u201321.","journal-title":"BJU Int"},{"key":"1319_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113360","volume":"194","author":"X Tan","year":"2023","unstructured":"Tan X, Wang Y, Wu Z, Zhou Q, Tang Y, Liu Z, et al. The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy. Eur J Cancer. 2023;194: 113360.","journal-title":"Eur J Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01319-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:14:39Z","timestamp":1746508479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01319-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1319"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01319-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"1 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This article does not contain any\u00a0studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}